Intuitive Surgical, Inc. $ISRG Holdings Boosted by Banque Cantonale Vaudoise

Banque Cantonale Vaudoise raised its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 29.9% in the first quarter, HoldingsChannel.com reports. The fund owned 14,732 shares of the medical equipment provider’s stock after buying an additional 3,387 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Intuitive Surgical were worth $6,792,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Brighton Jones LLC boosted its holdings in shares of Intuitive Surgical by 24.9% during the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock valued at $1,916,000 after acquiring an additional 731 shares during the period. Sivia Capital Partners LLC grew its position in shares of Intuitive Surgical by 3.8% during the second quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock worth $504,000 after acquiring an additional 34 shares during the last quarter. Schnieders Capital Management LLC. increased its holdings in shares of Intuitive Surgical by 38.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 973 shares of the medical equipment provider’s stock worth $529,000 after acquiring an additional 268 shares during the period. Osterweis Capital Management Inc. bought a new stake in Intuitive Surgical in the 2nd quarter valued at about $200,000. Finally, Main Street Financial Solutions LLC lifted its position in Intuitive Surgical by 92.4% in the 2nd quarter. Main Street Financial Solutions LLC now owns 2,929 shares of the medical equipment provider’s stock valued at $1,592,000 after purchasing an additional 1,407 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Trading Down 0.4%

Shares of NASDAQ ISRG opened at $401.77 on Thursday. Intuitive Surgical, Inc. has a twelve month low of $396.68 and a twelve month high of $603.88. The firm has a 50-day moving average of $435.29 and a two-hundred day moving average of $486.41. The company has a market capitalization of $142.29 billion, a price-to-earnings ratio of 48.70, a PEG ratio of 3.28 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.08 by $0.42. The company had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.62 billion. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The business’s revenue was up 23.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.81 EPS. As a group, research analysts predict that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current year.

Insider Buying and Selling at Intuitive Surgical

In other news, SVP Iman Jeddi sold 5,625 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $420.55, for a total transaction of $2,365,593.75. Following the completion of the sale, the senior vice president owned 6,463 shares in the company, valued at approximately $2,718,014.65. This represents a 46.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of the stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $424.14, for a total value of $169,656.00. Following the sale, the executive vice president owned 5,720 shares of the company’s stock, valued at $2,426,080.80. This trade represents a 6.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 7,169 shares of company stock valued at $3,059,135. Corporate insiders own 0.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ISRG shares. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Intuitive Surgical from $440.00 to $366.00 and set a “sell” rating for the company in a research note on Tuesday, June 2nd. TD Cowen decreased their price objective on Intuitive Surgical from $660.00 to $585.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Piper Sandler reaffirmed an “overweight” rating and set a $580.00 target price on shares of Intuitive Surgical in a research note on Tuesday, June 2nd. Wall Street Zen raised Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Finally, Evercore reduced their price target on Intuitive Surgical from $550.00 to $480.00 and set a “neutral” rating for the company in a research report on Monday, April 6th. Nineteen equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus price target of $573.42.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Several articles highlight that ISRG still has strong fundamentals, including rising procedure demand, solid revenue growth, and continued AI-driven innovation, which support a constructive long-term view. ISRG vs. ZBH: Which Robotic Surgery Stock Offers Better Upside Now?
• Positive Sentiment: Intuitive Surgical recently raised its 2026 outlook, including higher da Vinci procedure growth guidance, signaling management confidence in continued adoption and demand. Is Procedure Growth Broad-Based Enough to Support ISRG’s 2026 Outlook?
• Neutral Sentiment: The stock is trending and heavily watched by investors, suggesting elevated attention but not necessarily a clear fundamental catalyst on its own. Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Some commentary says ISRG can act as a hedge against broader market risk, reinforcing its defensive quality rather than pointing to a near-term catalyst. What Makes Intuitive Surgical (ISRG) a Hedge Against Market Risk?
• Negative Sentiment: Deutsche Bank maintained a Sell rating and cut its price target on ISRG to $366 from $440, adding to bearish sentiment around the shares. Deutsche Bank Maintains a Sell Rating on Intuitive Surgical (ISRG), Here’s Why
• Negative Sentiment: Jim Cramer also struck a cautious tone, saying ISRG faces “too much competition,” which may be weighing on sentiment despite the company’s strong market position. Jim Cramer on Intuitive Surgical: “Too Much Competition”
• Negative Sentiment: Broader coverage notes ISRG has already fallen sharply in 2026, and analysts have recently trimmed expectations, which may be contributing to the stock’s weakness. Goldman Sachs Intuitive Surgical call goes against the grain

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.